IDO1 and neoplasm: It has been shown that prostaglandin E2 (PGE2) expression in a cancer setting induces regulatory T cells, promotes T cell anergy through direct effects on T cells and indirect effects via antigen presenting cells (APCs) (27), thus, like IDO, shifting the immune system toward a tolerogenic phenotype and promoting tumor progression.